Search

Your search keyword '"A. P. Pagano"' showing total 13 results
Start Over Author "A. P. Pagano" Journal leukemia
13 results on '"A. P. Pagano"'

1. Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9)

Author

Cesaro, Simone, Mikulska, Malgorzata, Hirsch, Hans H., Styczynski, Jan, Meylan, Sylvain, Cordonnier, Catherine, Navarro, Davide, von Lilienfeld-Toal, Marie, Mehra, Varun, Marchesi, Francesco, Besson, Caroline, Masculano, Raul Cordoba, Beutel, Gernot, Einsele, Herman, Maertens, Johan, de la Camara, Rafael, Ljungman, Per, and Pagano, Livio

Published
2023
Full Text
View/download PDF

2. Frequently asked questions regarding SARS-CoV-2 in cancer patients—recommendations for clinicians caring for patients with malignant diseases

Author

von Lilienfeld-Toal, Marie, Vehreschild, Jörg Janne, Cornely, Oliver, Pagano, Livio, Compagno, Francesca, and Hirsch, Hans H

Subjects
Prevention, Lung, Clinical Research, Infectious Diseases, Hematology, Patient Safety, Vaccine Related, Rare Diseases, Emerging Infectious Diseases, Biodefense, Cancer, Infection, Good Health and Well Being, Betacoronavirus, COVID-19, Coronavirus Infections, Humans, Infection Control, Infectious Disease Transmission, Patient-to-Professional, Neoplasms, Pandemics, Patient Care, Pneumonia, Viral, Practice Guidelines as Topic, SARS-CoV-2, EHA Infectious Disease Scientific Working Group, Clinical Sciences, Oncology and Carcinogenesis, Immunology
Abstract

Since early 2020, the SARS-CoV-2 pandemic has a massive impact on health care systems worldwide. Patients with malignant diseases are assumed to be at increased risk for a worse outcome of SARS-CoV-2 infection, and therefore, guidance regarding prevention and management of the infection as well as safe administration of cancer-therapy is required. Here, we provide recommendations for the management of patients with malignant disease in the times of COVID-19. These recommendations were prepared by an international panel of experts and then consented by the EHA Scientific Working Group on Infection in Hematology. The primary aim is to enable clinicians to provide optimal cancer care as safely as possible, since the most important protection for patients with malignant disease is the best-possible control of the underlying disease.

Published
2020

3. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)

Author

Cesaro, Simone, Ljungman, Per, Mikulska, Malgorzata, Hirsch, Hans H., von Lilienfeld-Toal, Marie, Cordonnier, Catherine, Meylan, Sylvain, Mehra, Varun, Styczynski, Jan, Marchesi, Francesco, Besson, Caroline, Baldanti, Fausto, Masculano, Raul Cordoba, Beutel, Gernot, Einsele, Herman, Azoulay, Elie, Maertens, Johan, de la Camara, Rafael, and Pagano, Livio

Published
2022
Full Text
View/download PDF

4. Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)

Author

Maschmeyer, Georg, Bullinger, Lars, Garcia-Vidal, Carolina, Herbrecht, Raoul, Maertens, Johan, Menna, Pierantonio, Pagano, Livio, Thiebaut-Bertrand, Anne, and Calandra, Thierry

Published
2022
Full Text
View/download PDF

6. Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)

Author

Maschmeyer, Georg, Bullinger, Lars, Garcia-Vidal, Carolina, Herbrecht, Raoul, Maertens, Johan, Menna, Pierantonio, Pagano, Livio, Thiebaut-Bertrand, Anne, and Calandra, Thierry

Published
2022
Full Text
View/download PDF

8. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition

Author

Sapienza, M R, Fuligni, F, Agostinelli, C, Tripodo, C, Righi, S, Laginestra, M A, Pileri, Jr, A, Mancini, M, Rossi, M, Ricci, F, Gazzola, A, Melle, F, Mannu, C, Ulbar, F, Arpinati, M, Paulli, M, Maeda, T, Gibellini, D, Pagano, L, Pimpinelli, N, Santucci, M, Cerroni, L, Croce, C M, Facchetti, F, Piccaluga, P P, and Pileri, S A

Published
2014
Full Text
View/download PDF

13. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis

Author

Martinelli, G, Mancini, M, De Benedittis, C, Rondoni, M, Papayannidis, C, Manfrini, M, Meggendorfer, M, Calogero, R, Guadagnuolo, V, Fontana, M C, Bavaro, L, Padella, A, Zago, E, Pagano, L, Zanotti, R, Scaffidi, L, Specchia, G, Albano, F, Merante, S, Elena, C, Savini, P, Gangemi, D, Tosi, P, Ciceri, F, Poletti, G, Riccioni, L, Morigi, F, Delledonne, M, Haferlach, T, Cavo, M, Valent, P, and Soverini, S

Abstract

The molecular basis of advanced systemic mastocytosis (SM) is not fully understood and despite novel therapies the prognosis remains dismal. Exome sequencing of an index-patient with mast cell leukemia (MCL) uncovered biallelic loss-of-function mutations in the SETD2 histone methyltransferase gene. Copy-neutral loss-of-heterozygosity at 3p21.3 (where SETD2 maps) was subsequently found in SM patients and prompted us to undertake an in-depth analysis of SETD2 copy number, mutation status, transcript expression and methylation levels, as well as functional studies in the HMC-1 cell line and in a validation cohort of 57 additional cases with SM, including MCL, aggressive SM and indolent SM. Reduced or no SETD2 protein expression—and consequently, H3K36 trimethylation—was found in all cases and inversely correlated with disease aggressiveness. Proteasome inhibition rescued SETD2 expression and H3K36 trimethylation and resulted in marked accumulation of ubiquitinated SETD2 in SETD2-deficient patients but not in patients with near-normal SETD2 expression. Bortezomib and, to a lesser extent, AZD1775 alone or in combination with midostaurin induced apoptosis and reduced clonogenic growth of HMC-1 cells and of neoplastic mast cells from advanced SM patients. Our findings may have implications for prognostication of SM patients and for the development of improved treatment approaches in advanced SM.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results